Dr Véronique Walsh joins BMS
This article was originally published in Scrip
Bristol-Myers Squibb has appointed Dr Véronique Walsh business unit director, neuroscience and immunoscience. She will lead the sales and marketing teams for the company's neuroscience and immunoscience portfolio, which includes Orencia (abatacept), Abilify (aripiprazole) and Perfalgan (paracetamol IV), as well as investigational products. Dr Walsh has 20 years' experience within the vaccines industry, most recently serving as deputy managing director in charge of market access, public affairs, communications, and strategic planning at Sanofi Pasteur MSD UK.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.